Liminatus Pharma Narrows H1 Loss Post-Merger, Raises Going Concern Doubts

TL;DR

**Liminatus Pharma's recent merger and cash infusion are a band-aid on a gaping wound; the 'going concern' warning means this pre-clinical biotech is still a high-risk bet.**

AI Summary

Liminatus Pharma, Inc. (LIMNW) reported a net income of $113,287 for the three months ended June 30, 2025, a significant improvement from a net loss of $(961,207) in the same period of 2024. However, for the six months ended June 30, 2025, the company still posted a net loss of $(214,239), albeit a substantial reduction from the $(2,715,185) loss in the prior year. Revenue was not reported, as the company is a pre-clinical stage biopharmaceutical firm. Key business changes include the consummation of a Business Combination on April 30, 2025, with Iris Acquisition Corp, resulting in the company's common stock and warrants trading on Nasdaq under 'LIMN' and 'LIMNW' respectively. This combination involved a PIPE Financing that brought in $15,000,000, including $10,556,500 in cash proceeds. The company's cash balance increased significantly to $1,338,222 as of June 30, 2025, from $56,319 at December 31, 2024. Despite these financial improvements and capital raises, management has concluded there is substantial doubt about its ability to continue as a going concern within one year due to an accumulated deficit of $28,879,455 and ongoing operational losses.

Why It Matters

For investors, Liminatus Pharma's successful Business Combination and PIPE financing, raising $15 million, provided a much-needed capital injection and Nasdaq listing, offering increased liquidity and visibility. However, the explicit 'substantial doubt about its ability to continue as a going concern' is a critical red flag, indicating significant financial instability despite the recent capital raise. Employees face uncertainty regarding job security if the company struggles to secure further funding. Customers, or rather future patients, are impacted by the potential delays or cessation of development for its immune-modulating cancer therapies, particularly IBA101, if financial issues persist. In the competitive biopharmaceutical market, Liminatus's pre-clinical stage and financial fragility put it at a disadvantage against better-capitalized rivals, making its ability to bring its candidate to market highly speculative.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about its ability to continue as a going concern within one year' due to an accumulated deficit of $28,879,455 as of June 30, 2025. While net income was $113,287 for Q2 2025, the six-month period still shows a net loss of $(214,239) and a loss from operations of $(1,382,431), indicating ongoing cash burn and significant financial instability.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the 'going concern' warning, potential investors should wait for clear evidence of sustained profitability or significant additional, non-dilutive financing before considering a position. Existing investors should re-evaluate their risk tolerance and consider reducing exposure.

Financial Highlights

debt To Equity

N/A

revenue

Not Applicable

operating Margin

N/A

total Assets

$1,908,781

total Debt

$10,716,193

net Income

$113,287

eps

Not Applicable

gross Margin

N/A

cash Position

$1,338,222

revenue Growth

N/A

Key Numbers

• $113,287 — Net income for Q2 2025 (Significant improvement from $(961,207) net loss in Q2 2024)
• $(214,239) — Net loss for H1 2025 (Reduced from $(2,715,185) net loss in H1 2024)
• $1,338,222 — Cash as of June 30, 2025 (Increased from $56,319 at December 31, 2024, largely due to PIPE financing)
• $28,879,455 — Accumulated deficit as of June 30, 2025 (Indicates significant historical losses and contributes to going concern doubt)
• $15,000,000 — Total consideration from PIPE Financing (Provided capital, including $10,556,500 in cash proceeds)
• 26,014,633 — Common shares outstanding as of June 30, 2025 (Increased from 17,500,000 at December 31, 2024, due to Business Combination and PIPE)
• $1,382,431 — Loss from operations for H1 2025 (Indicates ongoing operational cash burn)
• $10,694,604 — Liabilities assumed from Iris (Assumed upon consummation of the Business Combination)

Key Players & Entities

• Liminatus Pharma, Inc. (company) — registrant and pre-clinical stage biopharmaceutical company
• Iris Acquisition Corp (company) — merger partner in the Business Combination
• Nasdaq (regulator) — stock exchange where LIMN and LIMNW began trading
• Cantor Fitzgerald & Co. (company) — underwriter for Iris's initial public offering
• Prophase Sciences, LLC (company) — related party involved in PIPE Financing
• Feelux Co, Ltd. (company) — received 4,000,000 shares of common stock as part of an agreement
• Car-Tcellkor, Inc. (company) — involved in an agreement with Feelux Co, Ltd. and Liminatus
• IBA101 (other) — Company's candidate, a humanized anti CD47 monoclonal antibody
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Liminatus Pharma faces substantial doubt about its ability to continue as a going concern within one year due to an accumulated deficit of $28,879,455 as of June 30, 2025. Despite a significant increase in cash to $1,338,222 following a business combination and PIPE financing, ongoing operational losses persist.
• Pre-Clinical Stage Operations [high — operational]: As a pre-clinical stage biopharmaceutical firm, Liminatus Pharma has not generated revenue and incurs significant operating expenses, primarily in general and administrative costs ($1,118,211 for Q2 2025) and historically in research and development. This lack of revenue generation necessitates continuous external funding.
• Dependence on Financing [high — financial]: The company's ability to fund its operations and development activities is heavily reliant on its access to capital markets and financing arrangements. The recent $15,000,000 PIPE Financing, which provided $10,556,500 in cash, highlights this dependence. Future funding needs remain significant.
• Biopharmaceutical Development Risks [medium — regulatory]: The development of biopharmaceutical products is subject to extensive regulatory review and approval processes by agencies like the FDA. Delays or failures in clinical trials or regulatory submissions can significantly impact the company's prospects and financial condition.
• High Operating Expenses [medium — financial]: Total operating expenses for Q2 2025 were $1,118,211, an increase from $909,218 in Q2 2024, driven by general and administrative costs. For H1 2025, operating expenses were $1,382,431, indicating continued burn rate despite the reduction from H1 2024's $2,619,729.
• Warrant and Debt Obligations [medium — financial]: The company has outstanding warrant liabilities ($200,450 as of June 30, 2025) and significant related party short-term debt ($1,442,500 as of June 30, 2025, down from $19,973,000 at Dec 31, 2024). Managing these obligations is crucial.

Industry Context

Liminatus Pharma operates in the highly competitive and capital-intensive biopharmaceutical industry. As a pre-clinical stage company, it faces significant hurdles in drug discovery, development, and regulatory approval. Success is contingent on innovation, robust clinical trial data, and substantial funding to navigate the lengthy and expensive path to market, often competing with established players and other emerging biotech firms.

Regulatory Implications

As a biopharmaceutical company, Liminatus Pharma is subject to stringent regulations from bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial protocols and rigorous approval processes. Any delays or setbacks in regulatory pathways pose significant risks to the company's development timeline and financial viability.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate progress in the drug development pipeline.
3. Assess the impact of the Business Combination and PIPE financing.

Key Dates

• 2025-04-30: Consummation of Business Combination with Iris Acquisition Corp — Marked a significant transition, leading to the company's common stock and warrants trading on Nasdaq under 'LIMN' and 'LIMNW', and facilitated a substantial capital raise.
• 2025-06-30: End of Second Quarter — Reported net income of $113,287 for the quarter, a substantial improvement from the prior year's loss, and ended the period with $1,338,222 in cash.
• 2025-06-30: End of First Half — Reduced net loss to $214,239 for the six months ended June 30, 2025, from $2,715,185 in the prior year, indicating progress in loss mitigation.

Glossary

Business Combination

A merger or acquisition transaction where two or more companies combine into a single entity. (Liminatus Pharma underwent a business combination with Iris Acquisition Corp, which was a pivotal event for its capital structure and public trading status.)

PIPE Financing

Private Investment in Public Equity. A way for public companies to raise capital by selling stock or warrants privately. (A $15,000,000 PIPE financing was crucial in bolstering Liminatus Pharma's cash position following the business combination.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Management has expressed substantial doubt about Liminatus Pharma's ability to continue as a going concern, highlighting financial risks.)

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by profits or additional paid-in capital. (Liminatus Pharma has a significant accumulated deficit of $28,879,455, underscoring its history of losses.)

Pre-clinical Stage

The phase of drug development before human testing, involving laboratory and animal studies to assess safety and efficacy. (Liminatus Pharma operates at this early stage, meaning it has no approved products and no revenue from drug sales.)

Year-Over-Year Comparison

Compared to December 31, 2024, Liminatus Pharma has seen a dramatic increase in its cash position, rising from $56,319 to $1,338,222, primarily due to the April 30, 2025 Business Combination and PIPE financing. Total assets have decreased significantly from $5,408,859 to $1,908,781, largely due to the reduction in current assets like loan receivable and deferred transaction costs. Liabilities have also decreased substantially from $24,748,922 to $10,716,193, reflecting a reduction in short-term debt and other payables. The company's accumulated deficit has slightly increased from $28,665,216 to $28,879,455, indicating continued operational losses despite the improved cash situation.

Key Financial Figures

• $1,442,500 — , 2025 and December 31, 2024, there was $1,442,500 and $ 19,973,000 , respectively, of rel

Filing Documents

• limn-20250630x10q.htm (10-Q) — 1085KB
• limn-20250630xex31d1.htm (EX-31.1) — 13KB
• limn-20250630xex31d2.htm (EX-31.2) — 13KB
• limn-20250630xex32d1.htm (EX-32.1) — 7KB
• limn-20250630xex32d2.htm (EX-32.2) — 7KB
• 0001104659-25-096872.txt ( ) — 5904KB
• limn-20250630.xsd (EX-101.SCH) — 59KB
• limn-20250630_cal.xml (EX-101.CAL) — 29KB
• limn-20250630_def.xml (EX-101.DEF) — 248KB
• limn-20250630_lab.xml (EX-101.LAB) — 412KB
• limn-20250630_pre.xml (EX-101.PRE) — 367KB
• limn-20250630x10q_htm.xml (XML) — 784KB

– Financial Information

Part I – Financial Information

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended June 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 26

Controls and Procedures

Item 4. Controls and Procedures 26

– Other Information

Part II – Other Information 27

Legal Proceedings

Item 1. Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 27

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 27

Other Information

Item 5. Other Information 27

Exhibits

Item 6. Exhibits 27

Signatures

Signatures 28 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Liminatus Pharma, Inc. (Successor to Iris Parent Holding Corp.) Condensed Consolidated Balance Sheets June 30, December 31, 2025 2024 ASSETS (Unaudited) Current assets Cash $ 1,338,222 $ 56,319 Loan receivable — 3,668,500 Deferred transaction costs — 1,401,323 Prepaid and other current assets 444,086 155,501 Total current assets 1,782,308 5,281,643 Non-current assets: Due from related party, non-current 126,275 126,275 Property and equipment, net 198 941 Total non-current assets 126,473 127,216 Total assets $ 1,908,781 $ 5,408,859 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued expenses $ 431,873 $ 1,483,253 Accrued interest, related parties 165,817 955,119 Accrued maintenance fee — 360,000 Due to research and development partner — 1,782,297 Due to related parties 170,553 195,253 Short-term debt, related parties 1,442,500 19,973,000 Deferred underwriting fee payable 500,000 — Deferred underwriting fee - common stock payable 7,805,000 — Total current liabilities 10,515,743 24,748,922 Warrant liability 200,450 — Total liabilities 10,716,193 24,748,922 Commitments and Contingencies (Note 7) Stockholders' deficit Preferred stock, $ 0.0001 par value; 1,000,000 shares authorized; none issued and outstanding* — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized; 26,014,633 and 17,500,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively* 2,601 1,750 Additional paid-in capital 20,069,442 9,323,403 Accumulated deficit ( 28,879,455 ) ( 28,665,216 ) Total stockholders' deficit ( 8,807,412 ) ( 19,340,063 ) Total liabilities and stockholders' deficit $ 1,908,781 $ 5,408,859 * Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to r

View Full Filing

View this 10-Q filing on SEC EDGAR